Matyas Gorjanacz

Prof. Matyas Gorjanacz

Bayer AG, Research & Development, Pharmaceuticals, Immuno-Oncology I
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 October 2017 in ACS Chemical Biology
Verified
Journal Article
Open access
AFAmaury E. Fernández-Montalván
Amaury E. Fernández-Montalván
MBMarkus Berger
Markus Berger
BKBenno Kuropka
Benno Kuropka
SKSeong Joo Koo
Seong Joo Koo
VBVolker Badock
Volker Badock
MGMatyas Gorjanacz
Matyas Gorjanacz
ATAD2 (ANCCA) is an epigenetic regulator and transcriptional cofactor, whose overexpression has been linked to the progress of various cancer types. Here, we report a DNA-encoded library screen leading to the discovery of BAY-850, a potent and isoform selective inhibitor that specifically induces ATAD2 bromodomain dimerization and prevents interactions with acetylated histones in vitro, as well as with chromatin in cells. These features qualify BAY-850 as a chemical probe to explore ATAD2 biology.

6 September 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
SKSeong Joo Koo
Seong Joo Koo
AFAmaury E. Fernández-Montalván
Amaury E. Fernández-Montalván
VBVolker Badock
Volker Badock
COChristopher J. Ott
Christopher J. Ott
SHSimon J. Holton
Simon J. Holton
MGMatyas Gorjanacz
Matyas Gorjanacz
ATAD2 is an epigenetic reader of newly synthesized histone marks during DNA replication

12 July 2017 in ACS Chemical Biology
Verified
Journal Article
Open access
MEManuel Ellermann
Manuel Ellermann
AEAshley Eheim
Ashley Eheim
FRFredrik Rahm
Fredrik Rahm
JVJenny Viklund
Jenny Viklund
JGJudith Guenther
Judith Guenther
MGMatyas Gorjanacz
Matyas Gorjanacz
MTH1 is a hydrolase responsible for sanitization of oxidized purine nucleoside triphosphates to prevent their incorporation into replicating DNA. Early tool compounds published in the literature inhibited the enzymatic activity of MTH1 and subsequently induced cancer cell death; however recent studies have questioned the reported link between these two events. Therefore, it is important to validate MTH1 as a cancer dependency with high quality chemical probes. Here, we present BAY-707, a substrate-competitive, highly potent and selective inhibitor of MTH1, chemically distinct compared to those previously published. Despite superior cellular target engagement and pharmacokinetic properties, inhibition of MTH1 with BAY-707 resulted in a clear lack of in vitro or in vivo anticancer efficacy either in mono- or in combination therapies. Therefore, we conclude that MTH1 is dispensable for cancer cell survival.

27 February 2018 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
FRFredrik Rahm
Fredrik Rahm
JVJenny Viklund
Jenny Viklund
LTLionel Trésaugues
Lionel Trésaugues
MEManuel Ellermann
Manuel Ellermann
AGAnja Giese
Anja Giese
MAMartin Andersson
Martin Andersson

10 June 2024 in Clinical and Experimental Medicine
Verified
Journal Article
Open access
PDF file
HRHelge G. Roider
Helge G. Roider
SHSabine Hoff
Sabine Hoff
STSu-Yi Tseng
Su-Yi Tseng
SBSandra Berndt
Sandra Berndt
MTMark Trautwein
Mark Trautwein
MGMatyas Gorjanacz
Matyas Gorjanacz
Regulatory T cells (Tregs) are known to facilitate tumor progression by suppressing CD8+ T cells within the tumor microenvironment (TME), thereby also hampering the effectiveness of immune checkpoint inhibitors (ICIs). While systemic depletion of Tregs can enhance antitumor immunity, it also triggers undesirable autoimmune responses. Therefore, there is a need for therapeutic agents that selectively target Tregs within the TME without affecting systemic Tregs. In this study, as shown also by others, the chemokine (C–C motif) receptor 8 (CCR8) was found to be predominantly expressed on Tregs within the TME of both humans and mice, representing a unique target for selective depletion of tumor-residing Tregs. Based on this, we developed BAY 3375968, a novel anti-human CCR8 antibody, along with respective surrogate anti-mouse CCR8 antibodies, and demonstrated their in vitro mode-of-action through induction of potent antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP) activities. In vivo, anti-mouse CCR8 antibodies effectively depleted Tregs within the TME primarily via ADCP, leading to increased CD8+ T cell infiltration and subsequent tumor growth inhibition across various cancer models. This monotherapeutic efficacy was significantly enhanced in combination with ICIs. Collectively, these findings suggest that CCR8 targeting represents a promising strategy for Treg depletion in cancer therapies. BAY 3375968 is currently under investigation in a Phase I clinical trial (NCT05537740).

27 January 2014 in Nucleus
Verified
Journal Article
Open access
MGMatyas Gorjanacz
Matyas Gorjanacz
Current anti-cancer therapies have a great deal of undesirable side effects; therefore, there is a need to develop efficient and cancer cell-specific new drugs without strong dose-limiting side eff...